| Literature DB >> 28881829 |
Liang Li1, Juying Jin1, Su Min1, Dan Liu1, Ling Liu1.
Abstract
We explored the effects of different levels of compliance with an enhanced recovery after surgery (ERAS) protocol on the short-term prognosis of patients who underwent colorectal cancer surgery. We conducted a single-center prospective cohort study in which 254 patients who received surgical treatment in a teaching tertiary care hospital were enrolled from March 2016 to November 2016. The patients were divided into four groups (I, II, III, and IV) based on individual compliance rates; the corresponding range of compliance rates was 0-60%, 60-70%, 70-80%, and 80-100%, and the number of patients in each group was 66, 63, 53, and 72, respectively. In the four groups from low to high compliance with ERAS (group I, II, III, and IV), the incidence of surgical site infections was 24.2%, 20.6%, 9.4%, and 6.9% (P < 0.05); the overall incidence of postoperative complications was 41.3%, 33.3%, 26.4%, and 16.7% (P < 0.05); the median length of postoperative hospital stay (in days) was 12.5, 10, 9, 8 (P < 0.05); and the median total hospital cost (Chinese Yuan) was 71,733, 73,632, 65,861, and 63,289 (P < 0.05), respectively. These results suggest that higher compliance with the ERAS protocol was associated with a lower incidence of surgical site infections, lower overall postoperative complication rate, shorter postoperative hospital stays, and lower total hospital costs.Entities:
Keywords: colorectal cancer; compliance; enhanced recovery after surgery; prognosis
Year: 2017 PMID: 28881829 PMCID: PMC5581128 DOI: 10.18632/oncotarget.18602
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flowchart of the study participant selection
ERAS protocol applied in the study
| 1. Preoperative counseling, patient education |
| 2. Nutritional assessment and enteral nutrition (Supportan or Fresubin 500 ml) support |
| 3. Cardiopulmonary function evaluation and optimization |
| 4. No preoperative bowel preparation |
| 5. Preoperative fasting time: 6-8 hours for solid food, 2 hours for clear liquids |
| 6. Oral intake of 400 ml carbohydrate drink: up to 2-3 hours before the induction of anesthesia (10% glucose solution) |
| 7. Intravenous antibiotics (cefoxitin 1.5 g or ceftriaxone 1 g) 30 minutes before incision |
| 8. No preanesthetic medication |
| 9. General anesthesia with rapid short-acting agents combined with TAP block |
| 10. Laparoscopic surgery |
| 11. Anesthesia depth monitoring with bispectral index or narcotrend index |
| 12. Intraoperative lung-protective ventilatory strategy |
| 13. Intraoperative neuromuscular monitoring |
| 14. Prevention of intraoperative hypothermia |
| 15. Intraoperative goal-directed fluid therapy and postoperative restrictive fluid administration |
| 16. Perioperative blood glucose control |
| 17. Multimodal prevention of PONV (5-HT3 receptor antagonist + dexamethasone + haloperidol) |
| 18. Multimodal prevention of DVT (physical prophylaxis combined with low molecular weight heparin administration) |
| 19. No nasogastric tube postoperatively |
| 20. Prevention of stress ulcer (perioperative administration of proton pump inhibitor) |
| 21. Multimodal management of postoperative pain (PCIA, TAP, NSAIDs, COX-2 inhibitor) |
| 22. Avoiding incision infection |
| 23. Early oral intake (drink water 2 hours after surgery, oral nutritional supplements on the first day after surgery, semi-solid diet on the second day after surgery) |
| 24. Early mobilization (out-of-bed activity for 2 hours on the first postoperative day and 4-6 hours from the second postoperative day to discharge) |
| 25. Removal of drainage tubes within three days after surgery |
| 26. Removal of urinary catheter as soon as possible (within 24 hours for colon surgery patients; within 48 hours for rectal surgery patients) |
TAP: transverse abdominis plane; PONV: postoperative nausea and vomiting; DVT: deep vein thrombosis; PCIA: patient-controlled intravenous analgesia; NSAIDs: nonsteroidal anti-inflammatory drugs.
Demographic characteristics and perioperative data
| I [0, 60%) | II [60%, 70%) | III [70%, 80%) | IV [80%, 100%] | P value | |
|---|---|---|---|---|---|
| 66 | 63 | 53 | 72 | ||
| 65 (53, 75) | 66 (54, 77) | 64 (50, 71) | 63.5 (52, 74) | 0.300 | |
| 39/27 | 31/32 | 31/22 | 39/33 | 0.644 | |
| 22.8 ± 2.9 | 21.4 ± 3.2 | 23.1 ± 3.0 | 22.4 ± 3.1 | 0.014 | |
| 0.042 | |||||
| II | 39 | 39 | 41 | 56 | |
| III | 26 | 24 | 12 | 15 | |
| IV | 1 | 0 | 0 | 1 | |
| 6 | 9 | 8 | 5 | 0.384 | |
| 21 | 19 | 12 | 22 | 0.702 | |
| 8 | 7 | 4 | 3 | 0.313* | |
| 3 | 7 | 5 | 5 | 0.655* | |
| 51/15 | 50/13 | 22/31 | 12/60 | < 0.001 | |
| 41/25 | 43/20 | 36/17 | 58/14 | 0.113 | |
| 121.4 ± 23.2 | 117.3 ± 21.6 | 122.2 ± 22.9 | 116.0 ± 23.8 | 0.356 | |
| 230 (200, 293) | 235 (215, 275) | 255 (187, 315) | 240 (192, 279) | 0.706 | |
| 100 (50, 200) | 100 (50, 200) | 100 (50, 100) | 80 (30, 100) | 0.003 | |
| 1897.7 ± 680.7 | 1732.2 ± 658.9 | 1555.7 ± 637.9 | 1538.3 ± 575.9 | 0.004 |
BMI: body mass index; ASA: American Society of Anesthesiologists; CHD: coronary heart disease; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; SD: standard deviation.
*Fisher exact test, all other statistics: Chi-Square test.
Comparison of compliance in the individual items of ERAS protocol
| Total | I [0, 60%) | II [60%, 70%) | III [70%, 80%) | IV [80%, 100%] | P value | |
|---|---|---|---|---|---|---|
| 254 | 66 | 63 | 53 | 72 | ||
| 254 (100%) | 66 (100%) | 63 (100%) | 53 (100%) | 72 (100%) | ||
| 119 (46.9%) | 20 (30.3%) | 26 (41.3%) | 26 (49.1%) | 47 (65.3%) | < 0.001 | |
| 214 (84.3%) | 39 (59.1%) | 54 (85.7%) | 49 (92.5%) | 72 (100%) | < 0.001 | |
| 35 (13.8%) | 4 (6.1%) | 4 (6.3%) | 7 (13.2%) | 20 (27.8%) | < 0.001 | |
| 207 (81.5%) | 40 (60.6%) | 52 (82.5%) | 46 (86.8%) | 69 (95.8%) | < 0.001 | |
| 154 (60.5%) | 15 (22.7%) | 29 (46.0%) | 42 (79.2%) | 68 (94.4%) | < 0.001 | |
| 254 (100%) | 66 (100%) | 63 (100%) | 53 (100%) | 72 (100%) | ||
| 231 (90.9%) | 53 (80.3%) | 59 (93.7%) | 51 (96.2%) | 68 (94.4%) | 0.013* | |
| 150 (59.1%) | 23 (34.8%) | 35 (55.6%) | 32 (60.4%) | 60 (83.3%) | < 0.001 | |
| 198 (78.0%) | 43 (65.2%) | 48 (76.2%) | 42 (79.2%) | 65 (90.3%) | 0.005 | |
| 229 (90.2%) | 52 (100%) | 58 (100%) | 51 (100%) | 68 (100%) | 0.004 | |
| 225 (88.6%) | 46 (69.7%) | 59 (93.7%) | 50 (94.3%) | 70 (97.2%) | < 0.001 | |
| 109 (42.9%) | 14 (21.2%) | 22 (34.9%) | 28 (52.8%) | 45 (62.5%) | < 0.001 | |
| 200 (78.7%) | 43 (65.2%) | 44 (69.8%) | 45 (84.9%) | 68 (94.4%) | < 0.001 | |
| 126 (49.6%) | 15 (22.7%) | 28 (44.4%) | 33 (62.3%) | 50 (69.4%) | < 0.001 | |
| 210 (82.7%) | 41 (62.1%) | 53 (84.1%) | 47 (88.7%) | 69 (95.8%) | < 0.001 | |
| 223 (87.8%) | 46 (69.7%) | 57 (90.5%) | 49 (92.5%) | 71 (98.6%) | < 0.001 | |
| 218 (85.8%) | 45 (68.2%) | 55 (87.3%) | 49 (92.5%) | 69 (95.8%) | < 0.001 | |
| 237 (93.3%) | 60 (90.9%) | 58 (92.1%) | 48 (90.6%) | 71 (98.6%) | 0.127* | |
| 233 (91.7%) | 58 (87.9%) | 57 (90.5%) | 48 (90.6%) | 70 (97.2%) | 0.170* | |
| 132 (52.0%) | 15 (22.7%) | 25 (39.7%) | 33 (62.3%) | 59 (81.9%) | < 0.001 | |
| 226 (89.0%) | 49 (74.2%) | 56 (88.9%) | 50 (94.3%) | 71 (98.6%) | < 0.001 | |
| 113 (44.5%) | 16 (24.2%) | 17 (27.0%) | 25 (47.2%) | 55 (76.4%) | < 0.001 | |
| 119 (46.9%) | 12 (18.2%) | 19 (30.2%) | 28 (52.8%) | 60 (83.3%) | < 0.001 | |
| 92 (36.2%) | 6 (9.1%) | 10 (15.9%) | 23 (43.4%) | 53 (73.6%) | < 0.001 | |
| 41 (16.1%) | 1 (1.5%) | 3 (4.8%) | 12 (22.6%) | 25 (34.7%) | < 0.001 |
*Fisher exact test, all other statistics: Chi-Square test.
The incidence of postoperative complications
| Total | I [0, 60%) | II [60%, 70%) | III [70%, 80%) | IV [80%, 100%] | P value | |
|---|---|---|---|---|---|---|
| 254 | 66 | 63 | 53 | 72 | ||
| 1 | 0 | 0 | 1 | 0 | 0.209* | |
| 1 | 1 | 0 | 0 | 0 | 0.717* | |
| 0 | 0 | 0 | 0 | 0 | ||
| 1 | 0 | 0 | 1 | 0 | 0.209* | |
| 2 | 2 | 0 | 0 | 0 | 0.170* | |
| 2 | 0 | 2 | 0 | 0 | 0.104* | |
| 0 | 0 | 0 | 0 | 0 | ||
| 5 | 2 | 1 | 1 | 1 | 0.933* | |
| 2 | 2 | 0 | 0 | 0 | 0.170* | |
| 1 | 0 | 0 | 1 | 0 | 0.224* | |
| 6 | 2 | 1 | 2 | 1 | 0.933* | |
| 5 | 1 | 3 | 1 | 0 | 0.233* | |
| 1 | 1 | 0 | 0 | 0 | 0.717* | |
| 1 | 0 | 0 | 0 | 1 | > 0.999* | |
| 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 0 | 0 | 0 | ||
| 1 | 1 | 0 | 0 | 0 | 0.717* | |
| 33 | 12 | 8 | 6 | 5 | 0.250 | |
| 3 | 1 | 0 | 1 | 1 | 0.890* | |
| 0 | 0 | 0 | 0 | 0 | ||
| 39 | 16 | 13 | 5 | 5 | 0.013 | |
| 0 | 0 | 0 | 0 | 0 | ||
| 4 | 1 | 3 | 0 | 0 | 0.086* | |
| 1 | 0 | 1 | 0 | 0 | 0.457* | |
| 73 | 26 | 21 | 14 | 12 | 0.023 |
POCD: postoperative cognitive dysfunction; SSIs: surgical site infections.
*Fisher exact test, all other statistics: Chi-Square test.
Figure 2Association between the compliance to the ERAS protocol and the incidence of postoperative complications. “*” indicates a significant difference compared to group I (P < 0.05), and the P value was corrected using Bonferroni’s method
Figure 3Association between the compliance rate of the ERAS protocol and the length of postoperative hospital stay. “*” indicates a significant difference compared to group I; “#” indicates a significant difference compared to group II. Analyzed using the Kruskal-Wallis test, P < 0.05
Post-discharge follow-up
| Total | I [0, 60%) | II [60%, 70%) | III [70%, 80%) | IV [80%, 100%] | P value | |
|---|---|---|---|---|---|---|
| 254 | 66 | 63 | 53 | 72 | ||
| 224 | 58 | 53 | 47 | 66 | 0.604 | |
| 14 | 3 | 5 | 3 | 3 | 0.722* | |
| 41 | 10 | 10 | 8 | 13 | 0.979 | |
| 3 | 1 | 0 | 2 | 0 | 0.128* |
*Fisher exact test, all other statistics: Chi-Square test.